NCT00706862Unknown3 期
FORTIS-C: A Phase 3, Randomized, Placebo-controlled Study of Oral Talactoferrin in Combination With Carboplatin and Paclitaxel as First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 发起方
- Agennix
- 入组人数
- 1,100
- 试验地点
- 6
- 主要终点
- Overall Survival
研究概览
简要总结
The purpose of the study is to determine whether the combination of talactoferrin, carboplatin and paclitaxel improves progression free survival and overall survival in patients with non-small cell lung cancer compared to the combination of paclitaxel and carboplatin alone
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Confirmed locally advanced or metastatic non-small cell lung cancer that is unresectable
- •At least 1 unirradiated target lesion measurable by RECIST
- •Adequate hematologic, renal and hepatic function
- •Able to understand and sign an Informed Consent
排除标准
- •Presence of brain metastases, unless the patient received brain irradiation, including adequate stereotactic radiosurgery, at least 4 weeks prior to randomization, and is stable, asymptomatic, and off steroids for at least 3 weeks prior to randomization
- •Received prior systemic anti-cancer therapy for NSCLC
- •History of allergic reactions to compounds of similar chemical or biologic composition to talactoferrin or the chemotherapy drugs
- •Any gastrointestinal tract disease or other medical condition resulting in the inability to take oral medications
- •History of other malignancies except: (i) adequately treated basal or squamous cell carcinoma of the skin; (ii) curatively treated, a) in situ carcinoma of the uterine cervix, b) prostate cancer, or c) superficial bladder cancer; or (iii) other curatively treated solid tumor with no evidence of disease for ≥5 years
- •Uncontrolled ischemic heart disease, or uncontrolled symptomatic congestive heart failure
- •Serious active infection
- •Psychiatric illness/social situations that would limit study compliance
- •Other uncontrolled serious chronic disease or conditions that in the investigator's opinion could render compliance or follow-up in the protocol problematic
- •Concurrent radiotherapy or radiotherapy within 4 weeks prior to randomization or previous radiotherapy at the indicator sites (the sites that are to be followed for determination of a response)
- •Concurrent systemic corticosteroid therapy within 4 weeks prior to randomization, except prophylactic use of steroids prior to paclitaxel administration
- •Known HIV positive or on active anti-retroviral therapy
- •Known Hepatitis B surface antigen positive or hepatitis C positive
- •Receipt of any investigational medication within 4 weeks prior to randomization
- •Pregnant or lactating patients, or fertile female patients with a positive pregnancy test, or fertile female patients unwilling to use adequate contraception during treatment and for 30 days after completion of treatment
- •Sexually active male patients unwilling to practice contraception while participating on the study and up to 30 days after completion of treatment
- •Legal incapacity or limited legal capacity, unless authorization is granted by a legal guardian
研究组 & 干预措施
1
Experimental
Talactoferrin, Carboplatin, Paclitaxel
干预措施: Talactoferrin (Drug)
2
Placebo Comparator
Placebo, Carboplatin, Paclitaxel
干预措施: Placebo (Drug)
结局指标
主要结局
Overall Survival
时间窗: After the occurence of the required number of events
Progression free survival
时间窗: At the time of final analysis
次要结局
- Objective response and disease stabilization rate(At the time of final analysis)
- Safety and tolerability(At the time of final analysis)
研究者
研究点 (6)
Loading locations...
相似试验
已完成
3 期
Safety and Efficacy of Talactoferrin in Previously Treated Patients With Non-small Cell Lung CancerNon Small Cell Lung CancerNCT00707304Agennix742
已完成
3 期
Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)Fallopian Tube CancerPeritoneal NeoplasmsOvarian CancerNCT03740165Merck Sharp & Dohme LLC1,367
已完成
3 期
Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by SurgeryRecurrent MelanomaStage IIIA Skin MelanomaStage IIIB Skin MelanomaStage IIIC Skin MelanomaStage IV Skin MelanomaMucosal MelanomaNCT00110019National Cancer Institute (NCI)823
进行中（未招募）
3 期
Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant ChemotherapyEstrogen Receptor NegativeHER2/Neu NegativeInvasive Breast CarcinomaProgesterone Receptor NegativeStage II Breast CancerStage IIA Breast CancerStage IIB Breast CancerStage III Breast CancerStage IIIA Breast CancerStage IIIB Breast CancerStage IIIC Breast CancerTriple-Negative Breast CarcinomaNCT02445391ECOG-ACRIN Cancer Research Group415
Unknown
2 期
Treatment of (IDA) by (FPC) Delivered Via Infusion Pump in Patients Receiving Home Infusion TherapyIron Deficiency AnemiaNCT05110768Rockwell Medical Technologies, Inc.75